|Bid||0.00 x 800|
|Ask||0.00 x 3200|
|Day's Range||99.97 - 100.00|
|52 Week Range||45.50 - 100.00|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2022 - Feb 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||97.86|
Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
PARK CITY, Utah, February 23, 2022--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021